<p>佛羅里達州邁爾斯堡 --（商業資訊）--NeoGenomics, Inc.（納斯達克代碼：NEO），一家領先的腫瘤診斷解決方案提供商，今天宣佈任命診斷和實驗室服務行業資深人士 John P. “Jack” Kenny 為其董事會成員。Kenny 先生將填補由 Alison Hannah 博士 vacated 的席位，後者在董事會服務超過十年後將卸任。</p>
<p>Kenny 先生為 NeoGenomics 董事會帶來了超過三十年的多元化高管、商業和運營經驗，以及在診斷和實驗室服務業務中的成功記錄。他最近擔任 Meridian Bioscience 的總裁、首席執行官和董事會成員，該公司是一家全面整合的生命科學公司，開發、製造和分銷廣泛的創新診斷產品和免疫測定及分子檢測公司的關鍵原材料。Meridian 曾在納斯達克交易所以 “VIVO” 代碼交易，於 2023 年 1 月被私有化。</p>
<p>“我們非常高興歡迎 Jack 加入 NeoGenomics 董事會，” NeoGenomics 董事會主席 Lynn Tetrault 表示。“他在建立成功文化和領導高績效商業團隊方面的豐富經驗，將在我們追求下一代癌症檢測的重要新興機會時為我們提供很大幫助，特別是在 NGS 和 MRD 領域。我期待他的見解和指導。”</p>
<p>“我還想感謝 Hannah 博士在過去十年中的戰略指導，以及她對 NeoGenomics 使命的堅定承諾，即通過改善患者護理來拯救生命。她的貢獻是無價的，” Tetrault 女士總結道。</p>
<p>在 2017 年加入 Meridian Bioscience 之前，Kenny 先生曾擔任西門子醫療北美區高級副總裁和總經理，之前則擔任貝克頓·迪金森美國地區副總裁和總經理。在他的職業生涯早期，他曾在 Leica Biosystems、Quest Diagnostics、西門子醫療解決方案和雅培實驗室擔任銷售領導職務。Kenny 先生還在 OraSure Technologies, Inc.、DCN Diagnostics 和 Quantum-Si, Inc.的董事會任職。他獲得了 Kettering University（前身為 GMI 工程與管理學院）管理系統學士學位，專注於市場營銷。</p>
<p>“我認識 NeoGenomics 已經很多年了，我相信他們在血液學癌症檢測中的領導地位使他們能夠將創新帶到最需要的地方——社區環境——改善患者結果，同時為股東創造持續價值，” Kenny 先生表示。“我期待與我的董事會同事和充滿激情的 NeoGenomics 領導團隊一起工作，幫助公司度過下一個增長階段。”</p>
<p><strong>關於 NeoGenomics</strong></p>
<p>NeoGenomics, Inc.是一家頂尖的癌症診斷公司，專注於癌症遺傳檢測和信息服務。我們提供涵蓋癌症全週期的最全面的腫瘤學檢測菜單之一，為腫瘤科醫生、病理學家、醫院系統、學術中心和製藥公司提供創新的診斷和預測檢測，幫助他們診斷和治療癌症。NeoGenomics 總部位於佛羅里達州邁爾斯堡，在美國運營一網絡的 CAP 認證和 CLIA 認證實驗室，提供全方位的樣本處理和分析服務，並在英國劍橋設有一家 CAP 認證的全方位樣本處理實驗室。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含前瞻性聲明。這些前瞻性聲明通常可以通過使用 “預期”、“期望”、“計劃”、“可以”、“可能”、“將”、“相信”、“估計”、“預測”、“目標”、“項目”、“指導”、“潛在” 等詞語來識別，儘管並非所有前瞻性聲明都包含這些詞。每一項前瞻性聲明都受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與這些聲明所表達或暗示的結果有實質性差異。適用的風險和不確定性包括但不限於在公司年度報告 10-K 表格、季度報告 10-Q 表格和公司向證券交易委員會提交的其他文件中列出的 “風險因素”。</p>
<p>我們提醒投資者不要對本新聞稿中的前瞻性聲明過於依賴。您被鼓勵閲讀我們向 SEC 提交的文件，這些文件可在 www.sec.gov 上找到，並在我們網站的 “投資者” 部分（ir.neogenomics.com）中討論這些及其他風險和不確定性。本新聞稿中的前瞻性聲明僅在本文件日期（除非另有説明）時有效，我們不承擔更新或修訂這些聲明的義務。我們的業務面臨重大風險和不確定性，包括上述提到的風險。投資者、潛在投資者和其他人應仔細考慮這些風險和不確定性。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMzA1NjU4NTFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMzA1NjU4NTFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251230565851/en/</p>
<p><strong>投資者聯繫</strong></p>
<p>Kendra Webster</p>
<p>InvestorRelations@neogenomics.com</p>
<p><strong>媒體聯繫</strong></p>
<p>Andrea Sampson</p>
<p>asampson@sampsonprgroup.com</p>
<p>來源：NeoGenomics, Inc.</p>

<p>NeoGenomics, Inc. 已任命 John P. "Jack" Kenny 為董事會成員，填補 Alison Hannah, MD 離開的席位。Kenny 在診斷和實驗室服務行業擁有超過 30 年的經驗，曾擔任 Meridian Bioscience 的總裁兼首席執行官。董事會主席 Lynn Tetrault 對 Kenny 在癌症檢測方面的專業知識以及他對公司增長的潛在貢獻表示興奮。NeoGenomics 專注於腫瘤學診斷解決方案，並在美國和英國運營獲得認證的實驗室</p>

<p>FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. “Jack” Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service.</p>
<div class="lb-trans"><p>佛羅里達州邁爾斯堡 --（商業資訊）--NeoGenomics, Inc.（納斯達克代碼：NEO），一家領先的腫瘤診斷解決方案提供商，今天宣佈任命診斷和實驗室服務行業資深人士 John P. “Jack” Kenny 為其董事會成員。Kenny 先生將填補由 Alison Hannah 博士 vacated 的席位，後者在董事會服務超過十年後將卸任。</p>
</div><p>Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully integrated life science company that develops, manufactures and distributes a broad range of innovative diagnostic products and critical raw materials for immunoassay and molecular testing companies. Meridian, which formerly traded on the NASDAQ exchange under the ticker “VIVO,” was taken private in January 2023.</p>
<div class="lb-trans"><p>Kenny 先生為 NeoGenomics 董事會帶來了超過三十年的多元化高管、商業和運營經驗，以及在診斷和實驗室服務業務中的成功記錄。他最近擔任 Meridian Bioscience 的總裁、首席執行官和董事會成員，該公司是一家全面整合的生命科學公司，開發、製造和分銷廣泛的創新診斷產品和免疫測定及分子檢測公司的關鍵原材料。Meridian 曾在納斯達克交易所以 “VIVO” 代碼交易，於 2023 年 1 月被私有化。</p>
</div><p>“We are very excited to welcome Jack to the NeoGenomics Board,” said Lynn Tetrault, Chair of the Board of NeoGenomics. “His vast experience building winning cultures and leading high performance commercial teams will serve us well as we pursue significant emerging opportunities in the next generation of cancer testing, notably NGS and MRD. I look forward to his insights and guidance.”</p>
<div class="lb-trans"><p>“我們非常高興歡迎 Jack 加入 NeoGenomics 董事會，” NeoGenomics 董事會主席 Lynn Tetrault 表示。“他在建立成功文化和領導高績效商業團隊方面的豐富經驗，將在我們追求下一代癌症檢測的重要新興機會時為我們提供很大幫助，特別是在 NGS 和 MRD 領域。我期待他的見解和指導。”</p>
</div><p>“I would also like to thank Dr. Hannah for her strategic guidance over the past decade and her unwavering commitment to NeoGenomics’ mission to save lives by improving patient care. Her contributions have been invaluable,” Ms. Tetrault concluded.</p>
<div class="lb-trans"><p>“我還想感謝 Hannah 博士在過去十年中的戰略指導，以及她對 NeoGenomics 使命的堅定承諾，即通過改善患者護理來拯救生命。她的貢獻是無價的，” Tetrault 女士總結道。</p>
</div><p>Prior to joining Meridian Bioscience in 2017, Mr. Kenny served as SVP and General Manager of North America at Siemens Healthcare and, before that, as VP and General Manager of the U.S. region at Becton Dickinson. Earlier in his career, he held sales leadership positions at Leica Biosystems, Quest Diagnostics, Siemens Medical Solutions, and Abbott Laboratories. Mr. Kenny also serves on the Boards of OraSure Technologies, Inc., DCN Diagnostics, and Quantum-Si, Inc. He received a BS in management systems with a focus in marketing from Kettering University (formerly the GMI Engineering and Management Institute).</p>
<div class="lb-trans"><p>在 2017 年加入 Meridian Bioscience 之前，Kenny 先生曾擔任西門子醫療北美區高級副總裁和總經理，之前則擔任貝克頓·迪金森美國地區副總裁和總經理。在他的職業生涯早期，他曾在 Leica Biosystems、Quest Diagnostics、西門子醫療解決方案和雅培實驗室擔任銷售領導職務。Kenny 先生還在 OraSure Technologies, Inc.、DCN Diagnostics 和 Quantum-Si, Inc.的董事會任職。他獲得了 Kettering University（前身為 GMI 工程與管理學院）管理系統學士學位，專注於市場營銷。</p>
</div><p>“I have known NeoGenomics for many years, and I believe their leadership position in hematology cancer testing positions them well to deliver innovation to where it’s needed most – the community setting – improving patient outcomes while creating sustained value for shareholders,” said Mr. Kenny. “I look forward to working alongside my fellow Board members and the passionate NeoGenomics leadership team to help guide the Company through its next phase of growth.”</p>
<div class="lb-trans"><p>“我認識 NeoGenomics 已經很多年了，我相信他們在血液學癌症檢測中的領導地位使他們能夠將創新帶到最需要的地方——社區環境——改善患者結果，同時為股東創造持續價值，” Kenny 先生表示。“我期待與我的董事會同事和充滿激情的 NeoGenomics 領導團隊一起工作，幫助公司度過下一個增長階段。”</p>
</div><p><strong>About NeoGenomics</strong></p>
<div class="lb-trans"><p><strong>關於 NeoGenomics</strong></p>
</div><p>NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.</p>
<div class="lb-trans"><p>NeoGenomics, Inc.是一家頂尖的癌症診斷公司，專注於癌症遺傳檢測和信息服務。我們提供涵蓋癌症全週期的最全面的腫瘤學檢測菜單之一，為腫瘤科醫生、病理學家、醫院系統、學術中心和製藥公司提供創新的診斷和預測檢測，幫助他們診斷和治療癌症。NeoGenomics 總部位於佛羅里達州邁爾斯堡，在美國運營一網絡的 CAP 認證和 CLIA 認證實驗室，提供全方位的樣本處理和分析服務，並在英國劍橋設有一家 CAP 認證的全方位樣本處理實驗室。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading &#34;Risk Factors&#34; contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明。這些前瞻性聲明通常可以通過使用 “預期”、“期望”、“計劃”、“可以”、“可能”、“將”、“相信”、“估計”、“預測”、“目標”、“項目”、“指導”、“潛在” 等詞語來識別，儘管並非所有前瞻性聲明都包含這些詞。每一項前瞻性聲明都受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與這些聲明所表達或暗示的結果有實質性差異。適用的風險和不確定性包括但不限於在公司年度報告 10-K 表格、季度報告 10-Q 表格和公司向證券交易委員會提交的其他文件中列出的 “風險因素”。</p>
</div><p>We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p>
<div class="lb-trans"><p>我們提醒投資者不要對本新聞稿中的前瞻性聲明過於依賴。您被鼓勵閲讀我們向 SEC 提交的文件，這些文件可在 www.sec.gov 上找到，並在我們網站的 “投資者” 部分（ir.neogenomics.com）中討論這些及其他風險和不確定性。本新聞稿中的前瞻性聲明僅在本文件日期（除非另有説明）時有效，我們不承擔更新或修訂這些聲明的義務。我們的業務面臨重大風險和不確定性，包括上述提到的風險。投資者、潛在投資者和其他人應仔細考慮這些風險和不確定性。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMzA1NjU4NTFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251230565851r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251230565851/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251230565851/en/</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫</strong></p>
</div><p>Kendra Webster</p>
<div class="lb-trans"><p>Kendra Webster</p>
</div><p>InvestorRelations@neogenomics.com</p>
<div class="lb-trans"><p>InvestorRelations@neogenomics.com</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫</strong></p>
</div><p>Andrea Sampson</p>
<div class="lb-trans"><p>Andrea Sampson</p>
</div><p>asampson@sampsonprgroup.com</p>
<div class="lb-trans"><p>asampson@sampsonprgroup.com</p>
</div><p>Source: NeoGenomics, Inc.</p>
<div class="lb-trans"><p>來源：NeoGenomics, Inc.</p>
</div>

NeoGenomics 任命診斷和實驗室服務行業資深人士 John P. “Jack” Kenny 加入其董事會 | NEO 股票新聞